Fate Therapeutics annual operating margin
2011
2012
2013
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Fate Therapeutics's operating margin was −2,222.45% for fiscal 2025.
View full Fate Therapeutics company overview| Fiscal year | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | −2,222.45% | −679.82 pp |
| 2024 | 2024-12-31 | −1,542.63% | −1242.77 pp |
| 2023 | 2023-12-31 | −299.86% | +20.37 pp |
| 2022 | 2022-12-31 | −320.23% | +68.32 pp |
| 2021 | 2021-12-31 | −388.56% | +18.91 pp |
| 2020 | 2020-12-31 | −407.47% | +535.66 pp |
| 2019 | 2019-12-31 | −943.14% | +472.31 pp |
| 2018 | 2018-12-31 | −1,415.44% | −389.51 pp |
| 2017 | 2017-12-31 | −1,025.94% | −299.84 pp |
| 2016 | 2016-12-31 | −726.10% | +416.72 pp |
| 2015 | 2015-12-31 | −1,142.82% | +677.47 pp |
| 2013 | 2013-12-31 | −1,820.29% | −1312.54 pp |
| 2012 | 2012-12-31 | −507.75% | +628.40 pp |
| 2011 | 2011-12-31 | −1,136.15% | — |
| Fiscal quarter | Period ended | Operating margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −1,495.39% | +443.15 pp |
| Q1 2026 | 2026-03-31 | −2,540.42% | −6.35 pp |
| Q4 2025 | 2025-12-31 | −2,536.23% | +783.55 pp |
| Q3 2025 | 2025-09-30 | −1,995.12% | −291.25 pp |
| Q2 2025 | 2025-06-30 | −1,938.54% | −1272.82 pp |
| Q1 2025 | 2025-03-31 | −2,534.07% | +118.81 pp |
| Q4 2024 | 2024-12-31 | −3,319.78% | −451.35 pp |
| Q3 2024 | 2024-09-30 | −1,703.87% | +933.94 pp |
| Q2 2024 | 2024-06-30 | −665.73% | +6040.06 pp |
| Q1 2024 | 2024-03-31 | −2,652.88% | −2604.41 pp |
| Q4 2023 | 2023-12-31 | −2,868.44% | −2723.20 pp |
| Q3 2023 | 2023-09-30 | −2,637.81% | −2061.14 pp |
| Q2 2023 | 2023-06-30 | −6,705.79% | −6257.74 pp |
| Q1 2023 | 2023-03-31 | −48.48% | +355.93 pp |
| Q4 2022 | 2022-12-31 | −145.23% | +261.30 pp |
| Q3 2022 | 2022-09-30 | −576.67% | −192.68 pp |
| Q2 2022 | 2022-06-30 | −448.05% | −99.27 pp |
| Q1 2022 | 2022-03-31 | −404.40% | +10.33 pp |
| Q4 2021 | 2021-12-31 | −406.53% | −196.42 pp |
| Q3 2021 | 2021-09-30 | −383.99% | +32.61 pp |
| Q2 2021 | 2021-06-30 | −348.78% | +176.50 pp |
| Q1 2021 | 2021-03-31 | −414.74% | +956.71 pp |
| Q4 2020 | 2020-12-31 | −210.11% | +827.65 pp |
| Q3 2020 | 2020-09-30 | −416.60% | +699.86 pp |
| Q2 2020 | 2020-06-30 | −525.29% | +329.66 pp |
| Q1 2020 | 2020-03-31 | −1,371.45% | −594.63 pp |
| Q4 2019 | 2019-12-31 | −1,037.76% | −29.87 pp |
| Q3 2019 | 2019-09-30 | −1,116.47% | +510.43 pp |
| Q2 2019 | 2019-06-30 | −854.95% | +1054.01 pp |
| Q1 2019 | 2019-03-31 | −776.82% | +592.96 pp |
| Q4 2018 | 2018-12-31 | −1,007.89% | −0.09 pp |
| Q3 2018 | 2018-09-30 | −1,626.90% | −694.15 pp |
| Q2 2018 | 2018-06-30 | −1,908.96% | +554.20 pp |
| Q1 2018 | 2018-03-31 | −1,369.79% | +102.28 pp |
| Q3 2017 | 2017-09-30 | −1,007.80% | −296.78 pp |
| Q2 2017 | 2017-06-30 | −932.75% | −241.46 pp |
| Q3 2013 | 2013-09-30 | −2,463.16% | — |
| Q2 2013 | 2013-06-30 | −1,472.07% | — |
| Q1 2013 | 2013-03-31 | −711.02% | — |
| Q3 2012 | 2012-09-30 | −691.29% | — |
Over the last five reported fiscal years, Fate Therapeutics's operating margin decreased from −407.47% to −2,222.45%, a change of −1814.98 percentage points. The latest reported quarter, Q2 2026, shows −1,495.39%.
Operating margin measures the percentage of revenue left after operating costs and expenses. It shows how much operating profit a company generates from each dollar of revenue.
TickerStat calculates operating margin as SEC-reported operating income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Fate Therapeutics filings at SEC.gov ↗